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Background and aims: Restructuring activities have been necessary during the lockdown phase of the coronavirus
disease 2019 (COVID-19) pandemic. Few data are available on the post-lockdown phase in terms of health-care
procedures in inflammatory bowel disease (IBD) care, and no data are available specifically from IBD units. We
aimed to investigate how IBD management was restructured during the lockdown phase, the impact of the
restructuring on standards of care and how Italian IBD units have managed post-lockdown activities.
Methods: A web-based online survey was conducted in two phases (April and June 2020) among the Italian Group
for IBD affiliated units within the entire country. We investigated preventive measures, the possibility of continuing
scheduled visits/procedures/therapies because of COVID-19 and how units resumed activities in the post-lockdown
phase.
Results: Forty-two referral centres participated from all over Italy. During the COVID-19 lockdown, 36% of first visits
and 7% of follow-up visits were regularly done, while >70% of follow-up scheduled visits and 5% of first visits were
done virtually. About 25% of scheduled endoscopies and bowel ultrasound scans were done. More than 80% of
biological therapies were done as scheduled. Compared to the pre-lockdown situation, 95% of centres modified
management of outpatient activity, 93% of endoscopies, 59% of gastrointestinal ultrasounds and 33% of biological
therapies. Resumption of activities after the lockdown phase may take three to six months to normalize. Virtual
clinics, implementation of IBD pathways and facilities seem to be the main factors to improve care in the future.
Conclusion: Italian IBD unit restructuring allowed quality standards of care during the COVID-19 pandemic to be
maintained. A return to normal appears to be feasible and achievable relatively quickly. Some approaches, such
as virtual clinics and identified IBD pathways, represent a valid starting point to improve IBD care in the post-
COVID-19 era.
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Introduction
The coronavirus disease 2019 (COVID-19) pandemic
has been one of the most dramatic challenges for
health-care systems worldwide. Presently, more than
9,000,000 people have been infected with severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2),
and more than 470,000 people have died because of
it.1 From February to May 2020, the huge numbers
of patients infected who needed hospitalization and
intensive care treatment overwhelmed hospitals and
clinics. All hospitals had to adapt their activities and
to reset their priorities, especially in those countries
that were greatly affected by the pandemic.2 Italy was
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the first European country to be affected by the vast
spread of COVID-19, especially in northern regions.
The Italian government was then forced to lock down
the country in order to contain the spread of infection
efficiently and to reduce the overload of patients
requiring medical care for COVID-19, with the lock-
down lasting from 10 March to 4 May 2020.
This restructuring of clinical activities also affected
inflammatory bowel disease (IBD) care.3 Virtual clin-
ics, remote monitoring and limiting procedures to only
those that are urgent (colonoscopies, imaging) have
been proposed in order to maintain the minimum
standards of care in IBD.3–5 Data from single IBD
referral centres suggest that such a restructuring
enabled an acceptable level of IBD care to be provided
during the lockdown phase.4,6–9
On the other hand, the restriction to only urgent
procedures and the need to maintain efficient measures
to avoid a resurgence of the virus in Italy requires the
structure and processes of IBD units to be adapted,
even in the post-lockdown phase (also called phase 2)
as a necessary transition to normalization.
Few data are available on the post-lockdown phase
in terms of health-care procedures,10,11 and no data are
available specifically from IBD units. For this reason,
the Italian Group for the study of Inflammatory Bowel
Disease (IG-IBD) aimed to investigate how IBD man-
agement was restructured during the lockdown phase,
what the impact of the restructuring was on the stand-
ards of care and how Italian IBD units have managed
phase 2 in terms of restructuring their daily activities.
Methods
A web-based online survey was conducted in two
phases (April and June, 2020) and with two different
questionnaires among IG-IBD affiliated IBD units
across the entire country. Before sending out the first
questionnaire, a call to participate was sent out to all
IBD centres currently affiliated to the IG-IBD, and the
same centres were invited to fill in the second question-
naire. A 47-item online questionnaire was sent-out to
all participants on 28 April 2020, investigating the pro-
portion of patients who did not experience any delay in
their scheduled visits/procedures/therapies because of
the COVID-19-related restructuring of their referral
IBD centre (primary outcome), and how units restruc-
tured their daily activities (health-care personnel (HCP)
allocation, virtual clinics, reschedule of infusions, visits,
endoscopies, imaging clinics) within the time period
between 10 March and 21 April 2020. On 26 May
2020, a second 23-item questionnaire was sent out
investigating how the same centres had structured
their daily activities since the beginning of phase 2, in
line with the most relevant questions from the first
questionnaire.
The study was approved and coordinated by the IG-
IBD Scientific Committee. As no individual patients
were enrolled, the study did not need to be approved
by local ethics committees. However, IG-IBD sent out
a letter to inform all participating institutions about
this survey.
Descriptive analysis was performed on the results of
the questionnaires. Categorical variables are presented
as proportions, and the number of patients who expe-
rienced delays/cancelations of their visits and proce-
dures are analysed as aggregate numbers.
Results
Of all the Italian IBD referral centres represented by
the active members of IG-IBD (N¼ 96), 42 (43.8%)
centres participated in the two phases of the survey,
and 22 (52.4%) were located in northern Italy.
Thirty-six (85.7%) centres were public hospitals, 23
(54.7%) were academic hospitals and 21 (50.0%)
actively followed up more than 1000 IBD patients.
Thirty-nine (92.9%) centres performed endoscopies,
35 (83.3%) had inpatients, 32 (76.2%) performed gas-
trointestinal ultrasound (GIUS) and 29 (69.5%) con-
ducted clinical trials.
IBD care restructuring during the lockdown
Between 10 March and 21 April 2020, none of the units
completely stopped their IBD activities, but 89% tem-
porarily stopped and postponed non-urgent activities
(outpatient clinics, endoscopies, GIUS), and 75%
needed to allocate some of their physicians and
nurses to COVID-19 inpatient care. Because of the
need for inpatient beds for severely ill COVID-19
patients, 80% of the IBD inpatient services restricted
IBD-related hospitalization to urgent cases only, and
7% moved IBD patients in other inpatient services. In
order to comply with the restrictions rules imposed by
the national and regional authorities, all units adopted
one or more policies to minimize the risk of infection
on site (Supplemental Figure S1).
Despite the national lockdown and the severe
restriction imposed, 36% of first visits and 7% of
follow-up visits were regularly done after a phone call
to assess their urgency, while >70% of scheduled
follow-up visits and 5% of first visits were done by
virtual clinics, as they were considered to be not
urgent. The remaining visits were cancelled or indefi-
nitely postponed. In contrast, >70% of endoscopies
and GIUS were cancelled or indefinitely postponed
(Figure 1).
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Seventy-nine per cent of patients needing to start
any intravenous (i.v.) biological therapy and 92% of
patients needing to start any subcutaneous (s.c.) bio-
logical therapy regularly received their first administra-
tions. Eighty-five per cent of patients in scheduled
maintenance i.v. biological therapy and 87% scheduled
maintenance s.c. biological therapy were able to con-
tinue. Only 1% of patients switched from i.v. to s.c.
biological therapy (Figure 2).
In centres participating in clinical trials, 7% stopped
all activities, and 17% made no changes. Of the
remaining 76%, the majority stopped new enrolments,
and almost half adopted virtual follow-up clinics.
IBD care in the post-lockdown phase
The resumption of the different activities in compari-
son with the pre-lockdown situation is shown in
Figure 3.
Compared to the pre-lockdown situation, 95.2% of
centres modified management of outpatient activity,
while modifications of endoscopies and GIUS were
reported by 92.9% and 59.2% of centres, respectively.
Clinical activity modifications consisted of a reduction
in procedures and in the implementation of virtual clin-
ics (around 90%), whereas endoscopy and GIUS mod-
ifications consisted of a reduction in the number of
procedures (>90%). An increase in dedicated time
and spaces occurred less frequently (Figure 4).
The management of biological therapies was modi-
fied in 33.3% of centres, mainly by increasing the ded-
icated time (58.8%) and preferring s.c. instead of i.v.
drugs for those patients who had to start a biological
therapy (35.3%). Of note, when possible, no patients
were switched from i.v. to s.c. administration during
the maintenance phase.
The available space for infusions and waiting rooms
was considered adequate to maintain the required dis-
tance among patients in 47.6% and 42.9% of centres,
respectively, whereas they were considered inadequate
and not adjustable in only 9.5% and 7.1% of centres,
respectively.
Changes in IBD care in the post-COVID era
Participants were also asked about their suggestions






















Figure 2. Management of scheduled administration of bio-
























Figure 1. Management of scheduled inflammatory bowel




























Figure 3. Resumption of IBD activities compared to before
lockdown.
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patients. Seventy-two per cent of centres expect that
IBD-related activity may return to pre-pandemic
levels within three to six months. Suggested solutions
to improve and maintain adequate standards of care
for IBD patients in the future included separating
IBD units from the rest of the gastroenterological
unit (60%), increasing the number of IBD health-care
professionals (51.%), increasing the dedicated time for
IBD care (29%) and adapting virtual clinics for follow-
up visits (19%; Figure 5). With regard to the change in
IBD patients’ needs and the impact of the pandemic on
their disease, in the future, 26.2% of responders expect
an increased number of flares, mainly due to psycho-
social stress and reduced compliance with medications
and monitoring. A further 23.8% expect an increased
need for information by the IBD HCP, and 19% expect
that patients will spontaneously modify their therapies.
Finally, the increase in virtual visits was the most
significant change that will probably be implemented
and maintained going forward (66.7% of responders;
Figure 6), together with more selective access to hospi-
tal (38%), improvement of diagnostic and therapeutic
pathways (33.3%) and closer interaction and collabo-
ration with general practitioners (24%).
No significant differences were observed between
centres located in northern Italy, the area most hit by
COVID-19, and the centres located in the other regions
of the country.
Discussion
The SARS-CoV-2 pandemic has had a huge impact on
daily health care for patients affected by chronic dis-
eases, including IBD. In many cases, scheduled on-site
visits and procedures have been delayed and even can-
celled in some cases.12,13 Since the early days of the
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Figure 5. Suggestions for the rapid resumption of IBD care
(more than one answer allowed).
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spread of the pandemic in Italy and then in Europe
soon after, IBD units needed to restructure their daily
activities to meet the needs of HCP and to provide the
facilities to treat COVID-19 patients.2,3,7,13 The impact
of restructuring on IBD patients has been poorly inves-
tigated in a large setting of IBD units nationwide.4,13
We conducted this survey to understand how IBD
centres in Italy managed IBD patients during the lock-
down phase, and how the restructuring has impacted
on the post-lockdown activities as they try to move
towards a return to normal. We found that the major-
ity of IBD units needed to reduce on-site procedures
for diagnosis and follow-up, such as outpatient clinics,
endoscopy and bowel ultrasound, in order to comply
with national regulations. Virtual clinics allowed the
monitoring of patients in follow-up and enabled the
regular monitoring of patients to continue in >70%
of cases. They were also important to allow regular
follow-up visits for clinical trials in 41% of cases.
With regard to biological therapies, the majority of
centres were able to start new therapies (74%) or main-
tain the scheduled regimen with i.v. drugs (85%). The
administration of s.c. drugs was also maintained in a
large majority of units (81%), and home delivery was
efficient in bypassing the lockdown restrictions in 16%
of units. All our findings substantially confirm what
has been reported by Spanish IBD units.13
The survey from phase 2 after the lockdown showed
that a return to normal is expected to take from three
to six months. In this transition phase, units need to
comply with some rules imposed by the national
authorities in order to reduce the risk of a resurgence
of the spread of SARS-COV2 infection. In particular,
units should ensure there is sufficient space to maintain
social distancing between patients and to avoid over-
crowding in waiting rooms. Our survey showed that
almost half of units have adequate facilities to
comply with these regulations, and will probably be
able to return to normal more quickly. Two months
after the end of the lockdown phase, activity has been
restored to 50% of the pre-COVID period. However,
those restrictions need to reschedule daily activities on
a larger amount of time per day and may probably
decrease the availability of time slots for IBD patients
compared to the pre-COVID era. For this reason,
physicians think that dedicated IBD units, an increase
in the number of HCP for IBD patients and virtual
clinics will be the best solutions to overcome this chal-
lenge. In fact, 66% believe that virtual clinics, identified
pathways of care and collaboration within a network of
specialists and general practitioners will be imple-
mented and used as a standard approach for the
follow-up of IBD patients, even after the COVID-19
pandemic is over, in line with the recent European
Crohn’s Colitis Organisation position paper on the
quality standards of care in IBD.14
Our survey has some limitations. About half of IBD
centres affiliated to IG-IBD participated in the survey.
However, this number includes almost all the centres
with the largest number of patients in active follow-up
in Italy, and includes centres from all regions of the
country, resulting in a representative and reliable
sample of the Italian situation during the study
period. Moreover, the measurement of the outcomes
in each IBD unit was compiled and evaluated based
only on self-reported data instead of using some objec-
tive measurements or a comparison with previous
activity in the same facilities. Finally, we were able to
measure the impact of the restructuring during the
lockdown phase but not in the post-lockdown phase
due to the short period of observation. This aspect
needs to be investigated in future studies.
In conclusion, restructuring of IBD units in Italy
enabled acceptable quality standard in IBD care to be
maintained, despite the huge impact of the COVID-19
pandemic in the country and the restrictions imposed
by the national lockdown, and may serve as a model
for IBD units in other countries. In particular, the
management of biological therapies and of urgent
activities in both the lockdown and phase 2 periods
substantially maintained the pre-pandemic standards
of care for IBD patients. However, the reductions in
number of visits, endoscopies and GIUS observed in
phase 2 might impair standards of care in the long
term, and require a longer period of time to return to
pre-pandemic levels. Virtual clinics and dedicated IBD
units with adequate facilities and the number
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Figure 6. Suggestions for improvements to IBD care in the
post-COVID-19 era (more than one answer allowed).
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post-lockdown phase, and should be maintained or
implemented even after the COVID-19 pandemic
has ended.
Further research is needed to investigate whether the
adjustments imposed because of the pandemic will
impact the quality of care for IBD patients in the
future. Indeed, some changes may have a positive
effect on the overall management, while others, such
as the postponement of routine examinations or colo-
rectal cancer surveillance endoscopies, may have a neg-
ative impact.
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